AR011577A1 - Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye - Google Patents

Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye

Info

Publication number
AR011577A1
AR011577A1 ARP980100352A ARP980100352A AR011577A1 AR 011577 A1 AR011577 A1 AR 011577A1 AR P980100352 A ARP980100352 A AR P980100352A AR P980100352 A ARP980100352 A AR P980100352A AR 011577 A1 AR011577 A1 AR 011577A1
Authority
AR
Argentina
Prior art keywords
transdermic
composition
drug
formulation including
administration
Prior art date
Application number
ARP980100352A
Other languages
English (en)
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR011577A1 publication Critical patent/AR011577A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composicion para la administracion transdérmica de una droga esteroide y formulacion transdérmica que la incluye, donde la composicion contiene unacantidad terapéuticamente efectiva de la droga; un promotor de absorcion que consisteesencialm ente de un dietilenglicol éter y un éster sorbitán; y unamatriz adhesiva farmacéuticamente aceptable, comprendiendo la formulacion una capa soporte protectora y una capa reservorio de droga, un lado de la cualestá laminado sobre lacapa protect ora y el otro lado está unido a una capa desprendible.
ARP980100352A 1997-01-27 1998-01-27 Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye AR011577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970002233A KR100215027B1 (ko) 1997-01-27 1997-01-27 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형

Publications (1)

Publication Number Publication Date
AR011577A1 true AR011577A1 (es) 2000-08-30

Family

ID=19495561

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100352A AR011577A1 (es) 1997-01-27 1998-01-27 Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye

Country Status (12)

Country Link
EP (1) EP1001812A1 (es)
JP (1) JP2000508349A (es)
KR (1) KR100215027B1 (es)
CN (1) CN1244806A (es)
AR (1) AR011577A1 (es)
AU (1) AU727811B2 (es)
BR (1) BR9807009A (es)
CA (1) CA2277970A1 (es)
ID (1) ID19755A (es)
RU (1) RU2176499C2 (es)
TW (1) TW537899B (es)
WO (1) WO1998032465A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100294084B1 (ko) * 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
AU2223600A (en) * 1999-01-06 2000-07-24 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
KR100403051B1 (ko) * 2000-07-25 2003-10-23 일양약품주식회사 음낭 외 피부에 적용가능한 남성호르몬 경피흡수 패취제
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
WO2004054544A1 (fr) * 2002-12-10 2004-07-01 Besins International Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant un progestatif et un oestrogene, son procede de preparation et ses utilisations
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
JP4422430B2 (ja) * 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
CN1313084C (zh) * 2004-11-05 2007-05-02 郑会义 一种透皮避孕药传送体系及制备方法
DE102004059880A1 (de) * 2004-12-10 2006-06-14 Grünenthal GmbH Stabiles, hormonhaltiges (Zwischen-)Produkt
JP4969050B2 (ja) * 2005-01-07 2012-07-04 ロート製薬株式会社 皮膚外用剤
JP2007045808A (ja) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd 皮膚外用剤
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
JP6004364B2 (ja) * 2011-10-14 2016-10-05 大正製薬株式会社 皮膚外用剤
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP5521025B2 (ja) * 2012-12-21 2014-06-11 日本精化株式会社 浸透促進剤
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPH0744940B2 (ja) * 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
CA1333114C (en) * 1987-11-25 1994-11-15 Daniel C. Duan Pressure-sensitive adhesives and bioelectrodes constructed with the adhesive
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JP3238389B2 (ja) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
EP0399432B1 (en) * 1989-05-25 1994-06-22 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents

Also Published As

Publication number Publication date
CN1244806A (zh) 2000-02-16
KR19980066583A (ko) 1998-10-15
BR9807009A (pt) 2000-03-14
AU5882098A (en) 1998-08-18
EP1001812A1 (en) 2000-05-24
RU2176499C2 (ru) 2001-12-10
WO1998032465A1 (en) 1998-07-30
KR100215027B1 (ko) 1999-08-16
JP2000508349A (ja) 2000-07-04
TW537899B (en) 2003-06-21
CA2277970A1 (en) 1998-07-30
AU727811B2 (en) 2000-12-21
ID19755A (id) 1998-07-30

Similar Documents

Publication Publication Date Title
AR011577A1 (es) Composicion para la administracion transdermica de una droga esteroide y formulacion transdermica que la incluye
US6277401B1 (en) Drug delivery device
ES2201434T3 (es) Sistema terapeutico transdermal para la administracion de hormonas.
AR043248A1 (es) Sistema terapeutico transdermico estable a los rayos uv
DK193389D0 (da) Transdermalt farmaceutisk system
CA2453013A1 (en) Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
KR940013496A (ko) 경피투여시스템
AR040822A1 (es) Un articulo absorbente y un metodo para hacer dicho articulo absorbente
DK0697860T3 (da) Estradiolholdigt transdermalt terapeutisk system
BR9815378A (pt) Sistema de fornecimento de droga transdérmico para agente analgésico antiinflamatório compreendendo sal de dietilamÈnio diclofenac e o método de fabricação do mesmo.
FI953533A0 (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
ES2139806T3 (es) Preparacion de absorcion percutanea que contiene dinitrato de isosorburo.
KR910009249A (ko) 활성 성분으로 부프레노르핀(Buprenorphine)을 함유하는 경피 치료 시스템
MY132338A (en) Estradiol-containing patch
AR041098A1 (es) Construccion de un refuerzo multilaminado
FI934189A0 (fi) Transdermalt terapeutiskt plaoster
DE50111208D1 (de) Matrixkontrolliertes transdermales system für stabile derivate der ace-hemmer
WO2002022109A3 (en) Patch comprising diclofenac
FI900315A0 (fi) Saett att framstaella ett ytligt terapeutiskt system vilket innehaoller tillvaext av elakartade celler och tillvaextfoerhindrande aktivaemne, speciellt 5-fluoruracil.
ES2057442T5 (es) Dispositivo para el suministro de estradiol por via transdermal y proceso de fabricacion de dicho dispositivo.
ES2178076T3 (es) Activador de celulas t citotoxicas y su empleo.
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
ES2138945T3 (es) Sistema de suministro transdermico de farmacos para el tratamiento de enfermedades cardiacas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal